In the current study, we found that both in CRC patients and those with ERBB2 alterations, EGFR/RAS/BRAF pathway, AKT/mTOR/PI3K pathway, and VEGFR signaling pathway alterations were observed most frequently. This evidence concerns the gene MTOR and colorectal carcinoma.